Medication info
Jardiance 10mg (Empagliflozin)

Jardiance 10mg (Empagliflozin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›10mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pale yellow, round film-coated tablet
Packaging
30 tablets/PTP [(10 tablets/PTP x 3)]
Approval status
Active

MFDS item code 202105533 · Approved 2021.07.23 · Insurance code 694004530

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this drug is 10 mg once daily, either as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of this drug is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular disease
View approved original text

This medication is used as an adjunct therapy to diet and exercise to effectively control blood glucose levels in adult patients with type 2 diabetes. It can also be used alone or in combination with other medications. It is particularly important to consult a healthcare professional when administering this medication to patients with insufficient blood glucose control who also have cardiovascular diseases. This medication helps prevent complications arising from diabetes and improves blood glucose levels.

How to take

Adult dose

The recommended dose of this drug is 10 mg once daily, either as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this drug is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this drug is administered concomitantly with a sulfonylurea or insulin, reducing the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This drug may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations • Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this drug should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this drug well but have a persistent estimated glomerular filtration rate < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This drug should be discontinued if the estimated glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this drug in patients with end-stage renal disease (ESRD) or receiving dialysis, as efficacy is not expected. • Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this drug is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. • Older adults No dose adjustment is necessary based on age. Renal function and the risk of volume depletion should be considered in patients 75 years of age or older. Initiation of this drug is not recommended in patients 85 years of age or older because clinical experience is limited (see Precautions for Use, section 4. General Precautions).

Precautions

This medication should not be administered to patients with hypersensitivity to the active ingredient or any components. It should not be used in patients with type 1 diabetes or diabetic ketoacidosis. This medication is not administered to patients with severely impaired kidney function, specifically those with a glomerular filtration rate below 30 mL/min/1.73m2, those with end-stage renal disease, or those undergoing dialysis. Since this medication contains lactose, it should not be used in patients with genetic lactose-related issues, such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Patients with a kidney function of less than 60 mL/min/1.73m2 should not initiate treatment with this medication, and those already under treatment may need dosage adjustments. If renal function drops below 45 mL/min/1.73m2, this medication should be discontinued. This medication is not expected to be effective in patients with end-stage renal disease or those undergoing dialysis. In patients with mild to moderate heart failure, it should be used cautiously, and it is not recommended for patients with severe heart failure. When combined with medications like insulin or sulphonylureas, the risk of hypoglycemia may be present, so dosage adjustments may be necessary. Be aware of possible adverse reactions during use, including hypoglycemia, genital infections, increased urination frequency, urinary tract infections, decreased fluid volume, increased serum creatinine, etc. Especially, ketoacidosis can be life-threatening, so if symptoms appear, promptly discontinue treatment and consult a healthcare professional. Elderly patients are at higher risk of fluid loss, so careful monitoring is required, and it is not recommended for patients over 85 years of age. For patients at risk of fluid loss, such as those with hypotension or cardiovascular disease, it should be administered with caution. Serious urinary infections such as urosepsis and pyelonephritis can occur, so if there are signs of infection, treatment should be initiated immediately. This medication may increase the risk of genital fungal infections, so patients with related medical history should be especially cautious. A positive urine glucose test may occur; consider this when interpreting test results. Be cautious of the risk of hypoglycemia when driving or operating machinery. It is recommended not to use this medication during pregnancy, and if pregnancy is confirmed, treatment should be discontinued. During breastfeeding, this medication may be excreted in breast milk, so it is advised to discontinue breastfeeding. The safety and efficacy in children under 18 years of age have not been established, so it should not be used in this population. In case of overdose, appropriate treatment based on clinical symptoms will be necessary, and studies on whether this medication can be removed by hemodialysis are not available. This medication should be stored out of reach of children, and it should not be transferred to another container.

Side effects

  • Hypoglycemia
  • vulvovaginitis
  • balanitis and other genital infections
  • urinary tract infections
  • perineal gangrene
  • ketoacidosis
  • pruritus
  • rash
  • urticaria
  • angioedema
Show 11 more
  • reduced fluid volume
  • increased urination
  • dysuria
  • interstitial nephritis
  • thirst
  • increased serum lipids
  • elevated blood creatinine
  • decreased glomerular filtration rate
  • increased hematocrit
  • urosepsis
  • pyelonephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pale yellow, round film-coated tablet

Package unit

30 tablets/PTP [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.